Navigating CIDP – Expert and Patient Perspectives

Episode 6. Mark Stettner and Karissa Gable discuss the real-world challenges of managing refractory CIDP, from defining meaningful treatment response to recognizing when stability is no longer sufficient. Drawing on recent clinical trial findings and evolving insights into CIDP pathophysiology, they explore decision-making beyond first-line therapies and what current evidence can – and cannot – tell us about long-term care. 

Episode 5. Mark Stettner is once again joined by Claudia Sommer to discuss patients’ experiences of CIDP from diagnosis through long-term management, reflecting on the questions, uncertainties, and emotional challenges they commonly face. Drawing on clinical experience and patient-reported insights, they consider how clear, individualized communication, careful expectation-setting, and shared decision-making help clinicians support informed, confident patients over time.

Episode 4. Claudia Sommer joins Mark Stettner to discuss how nodal and paranodal antibodies have reshaped our understanding of CIDP, from early discoveries in neurofascin, contactin, and CASPR1 antibodies to their recognition as distinct disease entities. The conversation also explores how antibody isotype, titer, and testing methodology influence diagnosis, prognosis, and therapeutic decision-making, offering practical insights for clinicians reassessing “atypical” CIDP cases.

Episode 3. Filip Eftimov joins Mark Stettner to examine the challenges of evaluating disease activity in CIDP, from interpreting clinical scales to balancing objective measures with patient-reported change. They highlight evolving treatment decisions, the importance of supportive therapies, and how biomarkers and digital tools may help refine long-term care.

Episode 2. Luis Querol and Mark Stettner address the challenges of CIDP misdiagnosis, from common mimics to borderline cases where diagnostic criteria alone may be insufficient. Their conversation outlines approaches to minimizing overtreatment, practical strategies for tapering or withdrawing therapy, and how emerging options, including FcRn inhibitors, can be integrated into real-world care.

Episode 1. Luis Querol and Mark Stettner unpack the complexity of CIDP guidelines, from navigating typical versus variant presentations to recognizing red flags that inform diagnostic confidence. They discuss why CIDP is best understood as a spectrum, how biology may eventually refine classification, and how first‑line treatment choices are influenced by real-world clinical considerations.